¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ - Á¦Ç° À¯Çüº°, µ¿¹° À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)
Veterinary Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product, By Animal Type, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1529634
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 10.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ Àü¸ÁÀ̸ç, 2030³â±îÁö 22¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
ÀÌ ½ÃÀåÀº ÁÖ·Î ¹Ý·Áµ¿¹° Àα¸¿Í »çÀ°·ü Áõ°¡, µ¿¹° ÁöÃâ Áõ°¡, ¿¹¹æÀû µ¿¹° ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀ» ²ø°í, µ¿¹° ºÐÀÚÁø´Ü ½ÃÇèÀÇ Áøº¸, Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇÏ´Â µ¿¹° °Ç° Áø´Ü¿¡ ´ëÇÑ ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡¿¡ ÀÇÇØ °ßÀεǾú½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 3¿ù, Biotangents´Â ¾Ï¼ÒÀÇ ¾Ï¼Ò ¹ÙÀÌ·¯½º¼º ¼³»ç ¹ÙÀÌ·¯½º(BVDV)¸¦ °ËÃâÇÏ´Â »õ·Î¿î ºÐÀÚÁø´Ü ºÐ¼®ÀÎ AmpliSpec LAB BVDV¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ºÐ¼®Àº µî¿Â ÁõÆø ¹æ¹ýÀ» »ç¿ëÇϹǷΠºñ¿ë È¿À²ÀûÀ̸ç 99.7%ÀÇ Á¤È®µµ¸¦ ³ªÅ¸³»¸ç BVD ´ëÃ¥¿¡ È¿°úÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀº ¹Ý·Áµ¿¹° Àα¸ Áõ°¡¿Í Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡¿¡ µû¶ó Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°Àº ¿µ±¹À» Æ÷ÇÔÇÏ¿© ¾î´À °¡Á¤¿¡³ª Æò¹üÇÏ°Ô ÀÖ½À´Ï´Ù. 2024³â Pet KeenÀÌ ¹ßÇ¥ÇÑ ±â»ç¿¡ µû¸£¸é ¿µ±¹ ¹Ý·Áµ¿¹° Àα¸´Â 2021³â¿¡´Â °³ 1,250¸¸ ¸¶¸®, °í¾çÀÌ 1,220¸¸ ¸¶¸®°¡ µÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¹Ý·Áµ¿¹°À» Ű¿ì´Â °¡Á¤ÀÌ ´Ã¾î³²¿¡ µû¶ó È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹Ý·Áµ¿¹° »çÀ° Áõ°¡´Â ºÐÀÚÁø´Ü ½ÃÇèÀ» Æ÷ÇÔÇÑ °í±Þ ¼öÀÇ ºÐÀÚÁø´Ü ¼ö¿ä¿¡ Á÷Á¢ ±â¿©ÇÕ´Ï´Ù. ÀÌ ¿¬±¸´Â ¹Ý·Áµ¿¹° °¨¿°, À¯Àü Áúȯ ¹× ±âŸ °Ç° »óŸ¦ ±âÁ¸ ¹æ¹ýº¸´Ù È¿°úÀûÀ¸·Î °¨ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±× °á°ú, PCR(ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ), ELISA(È¿¼Ò °áÇÕ ¸é¿ªÈíÂø ÃøÁ¤¹ý), ±âŸ ºÐÀÚ±â¼úÀÇ Çõ½ÅÀÌ ¼öÀÇ ºÐÀÚÁø´Ü Á¤¹Ðµµ¿Í Ä¡·á ¼ºÀû Çâ»ó¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀº ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡¿¡ ºÎÀÀÇϱâ À§ÇØ ±Þ¼ÓÈ÷ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
PCR ±â¹Ý µ¿¹° Áø´Ü Å×½ºÆ®´Â ½Å¼ÓÇÑ °á°ú, ¹Î°¨¼º ¹× ƯÀ̼º Çâ»ó, ºñ¿ë È¿°ú, Æ÷ÀÎÆ® ¿Àºê Äɾî Å×½ºÆ® ½ÇÇà ´É·Â µîÀÇ ÀÌÁ¡À» Á¦°øÇÏ¿© ½ÃÀå ¼ö¿ä Áõ°¡¿¡ ±â¿©ÇÕ´Ï´Ù. ½ÃÀåÀÇ ÀϺΠÁÖ¿ä ±â¾÷Àº IDEXX RealPCR Å×½ºÆ®, Qiagen VetMAX PCR ŰƮ, BioChek PCR ŰƮ¿Í °°Àº PCR ±â¹Ý Áø´Ü Å×½ºÆ® ŰƮ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¿©·¯ º´¿øÃ¼¸¦ µ¿½Ã¿¡ °ËÃâÇϱâ À§ÇÑ ¸ÖƼÇ÷º½º PCR ºÐ¼® µî, PCR ±â¹Ý Áø´Ü ½ÃÇèÀÇ ±â´ÉÀ» °ÈÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ¿Í ½ÅÈï±¹ ½ÃÀåÀÇ ¼ºÀåÀº µ¿¹°¿ë ºÎ¹®ÀÇ ÁøÈÇÏ´Â ¿ä±¸¿¡ ´ëÀÀÇÔÀ¸·Î½á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù, HORIBA UK Veterinary´Â POCKIT Central Analyzer¸¦ À§ÇÑ ÀÚ»ç PCR Á¦Ç° ¶óÀÎÀÇ ÀϺηΠ¿£¼¼ÆÄ¸®Æ® Á¸ Äí´ÏŬ¸®(E. cuniculi)¸¦ °ËÃâÇϱâ À§ÇÑ »õ·Î¿î ½ÃÇèÀ» µµÀÔÇß½À´Ï´Ù. ÀÌ Ãß°¡·Î ¹Ý·Áµ¿¹°°ú °¡Ãà°ú °ü·ÃµÈ ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ, ±â»ýÃæ, ¿øÃæ°ú °°Àº »ç¿ë °¡´ÉÇÑ ½ÃÇè Ç׸ñÀº 200 °¡±îÀÌ·Î Å©°Ô È®´ëµÇ¾ú½À´Ï´Ù.
¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Á¦Ç°º°·Î´Â °Ë»ç ŰƮ ¹× ½Ã¾à ºÎ¹®ÀÌ 2023³âÀÇ ¸ÅÃâ Á¡À¯À² 47% ÀÌ»óÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ±×·¯³ª ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÇè ŰƮÀÇ ±â¼ú Áøº¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó 2024³âºÎÅÍ 2030³â±îÁö CAGRÀº ±â±â ºÎ¹®ÀÌ 10.7%·Î °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
- µ¿¹° À¯Çüº°·Î´Â 2023³â¿¡ ¹Ý·Áµ¿¹° ¼¼ºÐȰ¡ ÃÖ´ëÀÇ ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇÏ¿´°í ¹Ý·Áµ¿¹° Àα¸ÀÇ ±ÞÁõ ¹× ¹Ý·Áµ¿¹°¿¡ ´ëÇÑ °í¾× ÁöÃâ¿¡ ÀÇÇØ 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
- ±â¼úº°·Î´Â PCR ºÎ¹®ÀÌ 2023³â¿¡ °¡Àå ³ôÀº ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. DNA ½ÃÄö½ÌÀº 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. PCR °Ë»ç ŰƮ´Â ¹Ý·Áµ¿¹°(¿¹ : °³ ÆÄº¸ ¹ÙÀÌ·¯½º ¹× °í¾çÀÌ ¹éÇ÷º´ ¹ÙÀÌ·¯½º) ¹× °¡Ãà(¿¹ : ¼Ò ¹ÙÀÌ·¯½º¼º ¼³»ç ¹ÙÀÌ·¯½º ¹× Á¶·ù ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º)ÀÇ °¨¿°°ú °°Àº ´Ù¾çÇÑ µ¿¹° º´¿øÃ¼ ¹× º´ÅÂÀÇ °ËÃâÀ» À§ÇØ »ç¿ë °¡´ÉÇÕ´Ï´Ù.
- ¿ëµµº°·Î´Â °¨¿° ºÎ¹®ÀÌ 2023³â¿¡ °¡Àå ³ôÀº ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â µ¿¹°ÀÇ Àü¿°º´ È®»êÀ» ¾ïÁ¦Çϱâ À§ÇØ ¿¹¹æ ÀÇ·á ÇÁ·Î±×·¥À» ½Ç½ÃÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÇÑÆí, À¯ÀüÇÐ ºÎ¹®Àº ¹Ý·Áµ¿¹°ÀÇ À¯Àüº´¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â µ¿¹° º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ 2023³â¿¡ ½ÃÀå¿¡¼ °¡Àå ³ôÀº ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇßÁö¸¸, À̰ÍÀº º´¿ø¿¡ ÀÖ¾î¼ÀÇ Áø´Ü ¼ö¿ä Áõ°¡¿Í ¿ëÀÌÇÏ°Ô ÀÌ¿ëÇÒ ¼ö Àִ ÷´Ü ºÐÀÚÁø´Ü ±â¼ú¿¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. ÀÌ ºÎ¹®Àº 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
- 2023³â ÃÖ´ë Á¡À¯À²Àº ºÏ¹Ì¿¡¼ ¾à 38%¸¦ Â÷ÁöÇß½À´Ï´Ù. ¹Ý´ë·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 11.6%·Î ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
- Çõ½ÅÀûÀÎ ºÐÀÚÁø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î º¸´Ù Á¤È®ÇÏ°í »ç¿ëÇϱ⠽±°í ºñ¿ë È¿À²ÀûÀÎ ¼öÀÇ ºÐÀÚÁø´Ü °Ë»ç ŰƮ°¡ °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå °èÅëÀÇ Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ºÐ¼® Åø
- COVID-19 ºÐ¼®
- ÁÖ¿ä ±¹°¡º° ÃßÁ¤ ¹Ý·Áµ¿¹° Àα¸
Á¦4Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : Á¦Ç°º° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : Á¦Ç°º°(2018-2030³â)
- ±â±â
- °Ë»ç ŰƮ ¹× ½Ã¾à
- ¼ÒÇÁÆ®¿þ¾î ¹× ¼ºñ½º
Á¦5Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : µ¿¹° À¯Çüº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : µ¿¹° À¯Çüº°(2018-2030³â)
- ¹Ý·Áµ¿¹°
- »ý»êµ¿¹°
Á¦6Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : ±â¼úº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : ±â¼úº°(2018-2030³â)
- PCR
- DNA ¼¿ ºÐ¼®
- ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
- INAAT ŰƮ
Á¦7Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : ¿ëµµº°(2018-2030³â)
- °¨¿°Áõ
- ´ë»çÁúȯ
- À¯ÀüÇÐ
- ±âŸ
Á¦8Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀÇ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð ¹× µ¿Ç⠺м® : ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
- µ¿¹°º´¿ø ¹× Ŭ¸®´Ð
- Áø´Ü ½ÇÇè½Ç
- ±âŸ
Á¦9Àå ¼öÀÇ ºÐÀÚÁø´Ü ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®
- Áö¿ª ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
- ºÏ¹Ì
- ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- µ§¸¶Å©
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- Áß±¹
- ÀϺ»
- Àεµ
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦10Àå °æÀï ±¸µµ
- ½ÃÀå ÁøÃâ±â¾÷ÀÇ ºÐ·ù
- ±â¾÷ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼® ¹× È÷Æ®¸Ê ºÐ¼®
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ÃßÁ¤ ºÐ¼®(2023³â)
- Àü·« ¸ÅÇÎ
- ÇÕº´ ¹× Àμö
- ÆÄÆ®³Ê½Ê ¹× Çù¾÷
- ±âŸ
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Zoetis
- IDEXX Laboratories, Inc.
- Antech Diagnostics, Inc.(Mars Inc.)
- Thermo Fisher Scientific Inc.
- Neogen Corporation
- Gold Standard Diagnostics(Eurofins Technologies)
- Bio-Rad Laboratories, Inc.
- Ring Biotechnology Co Ltd.
- QIAGEN NV
- BIONOTE
Á¦11Àå Áß¿äÇÑ Æ÷ÀÎÆ®
AJY
¿µ¹® ¸ñÂ÷
Veterinary Molecular Diagnostics Market Growth & Trends:
The global veterinary molecular diagnostics market size is expected to reach USD 2.23 billion by 2030, registering a CAGR of 10.5 % from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, an increasing focus on preventative animal healthcare, and advances in veterinary molecular diagnostic testing, and growing R&D investment in animal health diagnostics to launch innovative products. For instance, in March 2023, Biotangents launched its AmpliSpec LAB BVDV, a new molecular diagnostic assay to detect Bovine Viral Diarrhoea Virus (BVDV) in cattle. The assay utilizes isothermal amplification for cost-effectiveness and shows 99.7% accuracy, which can be used to combat BVD effectively.
Furthermore, the veterinary molecular diagnostics market has grown significantly due to the rising pet population and the increasing need for accurate diagnostic tools. Pets are commonly found in homes everywhere, including in the UK. According to the article published by Pet Keen in 2024 stated that the pet population in the UK was estimated to be 12.5 million dogs & 12.2 million cats in 2021. As more households adopt companions into their homes, there's an increased demand for efficient and accessible healthcare solutions. This increase in pet ownership has directly contributed to the demand for advanced veterinary diagnostics, including molecular diagnostics tests. These tests are crucial for detecting infectious diseases, genetic disorders, and other health conditions in pets more effectively than traditional methods. As a result, the veterinary molecular diagnostics market is expanding rapidly to meet these growing demands, with innovations in PCR (Polymerase Chain Reaction), ELISA (Enzyme-Linked Immunosorbent Assay), and other molecular techniques playing a pivotal role in improving diagnostic accuracy and treatment outcomes for animals.
PCR-based veterinary diagnostic tests offer the advantages of faster results, increased sensitivity & specificity, cost-effectiveness, and the ability to perform point-of-care testing, contributing to their growing demand in the market. Some key players in the market are offering PCR-based diagnostic test kits like IDEXX RealPCR tests, Qiagen VetMAX PCR Kits, and BioChek PCR Kits. Furthermore, ongoing investments in research & development aimed at enhancing the capabilities of PCR-based diagnostic tests, such as multiplex PCR assays for simultaneous detection of multiple pathogens, and growing product launches are driving market growth by addressing the evolving needs of the veterinary sector. For instance, in September 2022, HORIBA UK Veterinary introduced a new test for detecting Encephalitozoon cuniculi (E. cuniculi) as part of its in-house PCR product line for the POCKIT Central analyzer. This addition significantly broadened the array of available tests to almost 200, encompassing viruses, bacteria, parasites, & protozoa related to companion animals and farm species.
Veterinary Molecular Diagnostics Market Report Highlights:
- Based on product, the test kits & reagents segment dominated the market with a revenue share of over 47% in 2023. However, the instruments segment is expected to grow at the fastest CAGR of 10.7% from 2024 to 2030 due to an increase in technological advancements in veterinary molecular diagnostic test kits.
- Based on animal type, the companion animals segment attributed to the largest revenue share in 2023 and is projected to grow at the fastest CAGR from 2024 to 2030 owing to a surge in pet population and high pet spending.
- Based on technology, the PCR segment accounted for the highest revenue share in 2023. DNA sequencing is projected to grow at the fastest CAGR from 2024 to 2030. PCR test kits are available for the detection of various veterinary pathogens and conditions, such as infectious diseases in companion animals (e.g., canine parvovirus & feline leukemia virus) and livestock (e.g., bovine viral diarrhea virus & avian influenza virus).
- Based on application, the infectious diseases segment held the highest revenue share in 2023 due to growing government initiatives to implement preventive healthcare programs to reduce the spread of infectious disease outbreaks in animals. On the other hand, the genetics segment is estimated to grow at the fastest CAGR from 2024 to 2030 due to growing awareness about genetic diseases in pets.
- Based on End use, veterinary hospitals & clinics segment held the highest revenue share of the market in 2023 owing to the increasing demand for diagnostics and readily accessible advanced molecular diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR from 2024 to 2030.
- North America attributed to the largest share of about 38% in 2023. Conversely, the Asia Pacific region is anticipated to grow fastest at CAGR of 11.6% from 2024 to 2030.
- Advances in innovative molecular diagnostic technology led to the development of more accurate, user-friendly, and cost-effective veterinary molecular diagnostic test kits. Such advancements are expected to drive market growth.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Regional Scope
- 1.1.2. Estimates And Forecast Timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis
- 1.6.2. Global Market: CAGR Calculation
- 1.7. Research Scope and Assumptions
- 1.7.1. List of Secondary Sources
- 1.7.2. List of Primary Sources
- 1.7.3. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Veterinary Molecular Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Drivers Analysis
- 3.2.1.1. Increasing Pet Population & Expenditure
- 3.2.1.2. Rising Prevalence Of Chronic Diseases in Animals
- 3.2.1.3. Growing Advancement In Technology
- 3.2.1.4. Increase in RD Expenditure
- 3.2.2. Market Restraints Analysis
- 3.2.2.1. Stringent Regulatory Requirements
- 3.2.2.2. Lack of awareness in developing regions.
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenges Analysis
- 3.3. Veterinary Molecular Diagnostics Market Analysis Tools
- 3.3.1. Porter's Analysis
- 3.3.1.1. Bargaining power of the suppliers
- 3.3.1.2. Bargaining power of the buyers
- 3.3.1.3. Threats of substitution
- 3.3.1.4. Threats from new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental Landscape
- 3.3.2.5. Legal landscape
- 3.4. Covid-19 Analysis
- 3.5. Estimated Pet Population, by key countries
Chapter 4. Veterinary Molecular Diagnostics Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Veterinary Molecular Diagnostics Market Movement Analysis
- 4.3. Global Veterinary Molecular Diagnostics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Instruments
- 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.5. Test Kits & Reagents
- 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.6. Software & Services
- 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Veterinary Molecular Diagnostics Market: Animal Type Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Veterinary Molecular Diagnostics Market Movement Analysis
- 5.3. Global Veterinary Molecular Diagnostics Market Size & Trend Analysis, by Animal Type, 2018 to 2030 (USD Million)
- 5.4. Companion Animal
- 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.2. Dogs
- 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Cats
- 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.4. Horses
- 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.4.5. Other Companion Animal
- 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5. Production Animal
- 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.2. Cattle
- 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.3. Poultry
- 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.4. Swine
- 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.5.5. Other Production Animal
- 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Veterinary Molecular Diagnostics Market: Technology Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Veterinary Molecular Diagnostics Market Movement Analysis
- 6.3. Global Veterinary Molecular Diagnostics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
- 6.4. PCR
- 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.5. DNA sequencing
- 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.6. Microarrays
- 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.7. INAAT Kits
- 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Veterinary Molecular Diagnostics Market: Application Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Veterinary Molecular Diagnostics Market Movement Analysis
- 7.3. Global Veterinary Molecular Diagnostics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 7.4. Infectious Disease
- 7.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5. Metabolic Disease
- 7.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.6. Genetics
- 7.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.7. Other Application
- 7.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Veterinary Molecular Diagnostics Market: End Use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Veterinary Molecular Diagnostics Market Movement Analysis
- 8.3. Global Veterinary Molecular Diagnostics Market Size & Trend Analysis, End Use, 2018 to 2030 (USD Million)
- 8.4. Veterinary Hospitals & Clinics
- 8.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5. Diagnostic Laboratories
- 8.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6. Others
- 8.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9. Veterinary Molecular Diagnostics Market: Regional Estimates & Trend Analysis
- 9.1. Regional Dashboard
- 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 9.3. North America
- 9.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.2. U.S.
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Competitive Insights
- 9.3.2.3. U.S. Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.3. Canada
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Competitive Insights
- 9.3.3.3. Canada Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.3.4. Mexico
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Competitive Insights
- 9.3.4.3. Mexico Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4. Europe
- 9.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.2. UK
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Insights
- 9.4.2.3. U.K. Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.3. Germany
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Insights
- 9.4.3.3. Germany Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.4. France
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Insights
- 9.4.4.3. France Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.5. Italy
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Competitive Insights
- 9.4.5.3. Italy Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.6. Spain
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Competitive Insights
- 9.4.6.3. Spain Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Competitive Insights
- 9.4.7.3. Sweden Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.8. Denmark
- 9.4.8.1. Key Country Dynamics
- 9.4.8.2. Competitive Insights
- 9.4.8.3. Denmark Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4.9. Norway
- 9.4.9.1. Key Country Dynamics
- 9.4.9.2. Competitive Insights
- 9.4.9.3. Norway Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5.2. China
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Insights
- 9.5.2.3. China Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.3. Japan
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Insights
- 9.5.3.3. Japan Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.4. India
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Competitive Insights
- 9.5.4.3. India Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.5. South Korea
- 9.5.5.1. Key Country Dynamics
- 9.5.5.2. Competitive Insights
- 9.5.5.3. South Korea Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.6. Australia
- 9.5.6.1. Key Country Dynamics
- 9.5.6.2. Competitive Insights
- 9.5.6.3. Australia Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.5.7. Thailand
- 9.5.7.1. Key Country Dynamics
- 9.5.7.2. Competitive Insights
- 9.5.7.3. Thailand Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.6. Latin America
- 9.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.2. Brazil
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Insights
- 9.6.2.3. Brazil Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.6.3. Argentina
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Insights
- 9.6.3.3. Argentina Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7. Middle East and Africa
- 9.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Key Country Dynamics
- 9.7.2.2. Competitive Insights
- 9.7.2.3. Saudi Arabia Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.3. South Africa
- 9.7.3.1. Key Country Dynamics
- 9.7.3.2. Competitive Insights
- 9.7.3.3. South Africa Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.4. UAE
- 9.7.4.1. Key Country Dynamics
- 9.7.4.2. Competitive Insights
- 9.7.4.3. UAE Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.7.5. Kuwait
- 9.7.5.1. Key Country Dynamics
- 9.7.5.2. Competitive Insights
- 9.7.5.3. Kuwait Veterinary Molecular Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Market Participant Categorization
- 10.2. Company Market Position Analysis/ Heat Map Analysis
- 10.3. Estimated Company Market Share Analysis, 2023
- 10.4. Strategy Mapping
- 10.4.1. Mergers & Acquisitions
- 10.4.2. Partnerships & Collaborations
- 10.4.3. Others
- 10.5. Company Profiles
- 10.5.1. Zoetis
- 10.5.1.1. Participant's Overview
- 10.5.1.2. Financial Performance
- 10.5.1.3. Product Benchmarking
- 10.5.1.4. Strategic Initiatives
- 10.5.2. IDEXX Laboratories, Inc.
- 10.5.2.1. Participant's Overview
- 10.5.2.2. Financial Performance
- 10.5.2.3. Product Benchmarking
- 10.5.2.4. Strategic Initiatives
- 10.5.3. Antech Diagnostics, Inc. (Mars Inc.)
- 10.5.3.1. Participant's Overview
- 10.5.3.2. Financial Performance
- 10.5.3.3. Product Benchmarking
- 10.5.3.4. Strategic Initiatives
- 10.5.4. Thermo Fisher Scientific Inc.
- 10.5.4.1. Participant's Overview
- 10.5.4.2. Financial Performance
- 10.5.4.3. Product Benchmarking
- 10.5.4.4. Strategic Initiatives
- 10.5.5. Neogen Corporation
- 10.5.5.1. Participant's Overview
- 10.5.5.2. Financial Performance
- 10.5.5.3. Product Benchmarking
- 10.5.5.4. Strategic Initiatives
- 10.5.6. Gold Standard Diagnostics (Eurofins Technologies)
- 10.5.6.1. Participant's Overview
- 10.5.6.2. Financial Performance
- 10.5.6.3. Product Benchmarking
- 10.5.6.4. Strategic Initiatives
- 10.5.7. Bio-Rad Laboratories, Inc.
- 10.5.7.1. Participant's Overview
- 10.5.7.2. Financial Performance
- 10.5.7.3. Product Benchmarking
- 10.5.7.4. Strategic Initiatives
- 10.5.8. Ring Biotechnology Co Ltd.
- 10.5.8.1. Participant's Overview
- 10.5.8.2. Financial Performance
- 10.5.8.3. Product Benchmarking
- 10.5.8.4. Strategic Initiatives
- 10.5.9. QIAGEN N.V.
- 10.5.9.1. Participant's Overview
- 10.5.9.2. Financial Performance
- 10.5.9.3. Product Benchmarking
- 10.5.9.4. Strategic Initiatives
- 10.5.10. BIONOTE
- 10.5.10.1. Participant's Overview
- 10.5.10.2. Financial Performance
- 10.5.10.3. Product Benchmarking
- 10.5.10.4. Strategic Initiatives
Chapter 11. Key Takeaways
°ü·ÃÀÚ·á